Experimental cell therapy offers hope for High-Risk blood cancer patients
NCT ID NCT07238686
Summary
This study is testing whether adding an infusion of donor immune cells to a standard drug regimen is safe and effective for treating intermediate- to high-risk myelodysplastic syndromes (MDS), a type of bone marrow cancer. It is for patients who cannot receive a standard stem cell transplant. Researchers will measure how well the treatment controls the disease and extends survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MYELODYSPLASTIC SYNDROMES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Department of Hematology, the Fifth Medical Center of Chinese PLA General Hospital
RECRUITINGBeijing, 100071, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.